Author

Dong-Yuan Zhu

h-index 4 View on Semantic Scholar

We have 3 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Efficacy and safety of risvutatug rezetecan versus gemcitabine plus docetaxel in relapsed/refractory advanced osteosarcoma: Primary results from the ARTEMIS-011 phase 3 trial.

BACKGROUND Patients with relapsed/refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. Herein, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase 3 trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Ch...

L. Xie, W. Yao, Y. Hua et al. · Annals of Oncology · 0 citations

Review Open access Aug 2026

HLX07, a novel anti-EGFR antibody, for locally advanced and metastatic cutaneous squamous cell carcinoma: an open-label, multicenter, phase II trial

HLX07 monotherapy has demonstrated promising efficacy and a favorable safety profile in treating aCSCC, warranting further investigation in large-scale clinical studies.

Chang-Xing Li, Kang Zeng, Dong-Yuan Zhu et al. · Therapeutic Advances in Medi... · 0 citations

Open access Aug 2026

Integrative cfDNA profiling from low-pass whole-genome sequencing enables tissue-of-origin prediction in cancer

This stacked ensemble machine learning classifier that integrates 11 multidimensional cfDNA features spanning genomic, fragmentomic, methylation/repeat, and microbial signals provides a robust and non-invasive approach for accurate cancer type identification and has the potential to support clinical decision-making.

Yunjian Zhang, Liang Liu, H. Bao et al. · Molecular Biomedicine · 0 citations